Back
82· Surging
Health & Science1h 52m ago
An independent panel of experts voted 11-0 that the benefits of the drug donanemab outweigh its risks for patients with early symptomatic Alzheimer's disease.
Silver Spring, Maryland, USA
Who
U.S. Food and Drug Administration (FDA) Advisory Committee
What
An independent panel of experts voted 11-0 that the benefits of the drug donanemab outweigh its risks for patients with early symptomatic Alzheimer's disease.
When
Wed, 10 Jun 2026 15:00:06 GMT · 1h 52m ago
Where
Silver Spring, Maryland, USA · 39.0331°N, 76.9906°W
Why
Clinical trial data demonstrated the drug significantly slowed cognitive and functional decline in patients with amyloid plaque buildup in the brain.
The Frontline Impact
How this affects you
This unanimous backing paves the way for a full FDA approval, offering a second effective treatment option for millions of families managing early-stage Alzheimer's.
Story chain
1 event in this threadNo related history yet — this is the origin event.
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.